Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy
Rachida Lebtahi, MD, PhD1,
Joseph Le Cloirec, MD2,
Claire Houzard, MD3,
Doumit Daou, MD1,
Iradj Sobhani, MD, PhD4,
Geneviève Sassolas, MD3,
Michel Mignon, MD, PhD4,
Patrick Bourguet, MD, PhD2 and
Dominique Le Guludec, MD, PhD1
1 Nuclear Medicine Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
2 Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France
3 Nuclear Medicine Department, Hôpital Universitaire Neuro-Cardiologique, Lyon, France
4 Gastroenterology Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France

View larger version (154K):
[in a new window]
|
FIGURE 1. Patient with nonfunctioning endocrine tumor. 111In-pentetreotide scintigraphy shows celiac tumors with liver metastases.
|
|

View larger version (143K):
[in a new window]
|
FIGURE 2. Same patient as in Figure 1. Celiac tumoral and liver metastases are not shown by 99mTc-P829 scintigraphy.
|
|

View larger version (150K):
[in a new window]
|
FIGURE 3. Patient with Zollinger-Ellison syndrome. 111In-pentetreotide scintigraphy shows multiple celiac tumors with liver and lung metastases.
|
|

View larger version (140K):
[in a new window]
|
FIGURE 4. Same patient as in Figure 3. 99mTc-P829 scintigraphy shows lung metastases (smaller than those shown by 111In-pentetreotide scintigraphy). Celiac tumors are not detected. Liver metastases are not clearly seen.
|
|
Copyright © 2002 by the Society of Nuclear Medicine.